Postoperative radiation therapy for gastric carcinosarcoma with c-kit expression: A case report

Takeshi Gohongi, Hiroyuki Iida, Naoto Gunji, Kazuo Orii, Takesaburo Ogata

Takeshi Gohongi, Hiroyuki Iida, Naoto Gunji, Kazuo Orii, Takesaburo Ogata, Department of Surgery and Pathology, Tsukuba-Gakuen Hospital, Ibaraki 305-0857, Japan

Author contributions: Gohongi T and Ogata T designed the report; Ogata T performed the pathologic studies; Gohongi T, Iida H, Gunji N and Orii K performed the surgery and treatment thereafter; and Gohongi T wrote the paper.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Takesaburo Ogata, MD, PhD, Department of Surgery and Pathology, Tsukuba-Gakuen Hospital, 2573-1 Kamiyokoba, Tsukuba, Ibaraki 305-0857, Japan. gohon@gakuen-hospital.or.jp

Telephone: +81-29-8361355
Fax: +81-29-8361590
Received: August 30, 2014
Peer-review started: August 31, 2014
First decision: September 27, 2014
Revised: November 13, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: March 7, 2015

Abstract

Gastric carcinosarcomas are rare morphologically biphasic tumors, consisting of carcinoma and sarcoma components, with a poor clinical course. Here we report the case of a 70-year-old man with advanced Borrmann type III carcinosarcoma arising from the upper body of the stomach with extensive lymph node metastasis who underwent a total, but palliative, gastrectomy. Histology showed the tumor consisted of a biphasic structure of tubular adenocarcinoma and spindle cell sarcoma. Immunohistochemistry revealed sarcoma cells expressing c-kit (CD117) and CD34, which are criteria for gastrointestinal stromal tumors. Nine months after the surgical operation, tumor metastases had extended to the hepatohilar, retroperitoneal and mediastinal lymph nodes. Radiation therapy of 50 Gy markedly decreased the size of each of these nodes and reduced the risk of respiratory complications and jaundice. However, the patient died of respiratory failure due to bronchopneumonia with multiple lung metastases 22 mo after resection. Autopsy revealed severe necrosis in most of the lymph nodes with tumor metastases. Radiation therapy combined with gastrectomy should be considered to improve survival in patients with gastric carcinosarcomas that express c-kit.

Key words: CD34; C-kit; Gastric carcinosarcoma; Radiation therapy; Gastrointestinal stromal tumor

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Gastric carcinosarcoma is a rare tumor for which there is no established definitive treatment. We present the first report of gastric carcinosarcoma with c-kit expression treated with neoadjuvant chemotherapy, surgical resection and radiation therapy. Radiation therapy to the metastatic tumors dramatically reduced their size and the patient survived 22 mo after surgery with a good quality of life. Although the relation between c-kit expression and radiation susceptibility remains unknown, this report provides new insight into the treatment of gastric carcinosarcoma for improved prognosis.
INTRODUCTION
Carcinosarcoma is a morphologically biphasic tumor comprised of carcinoma and sarcoma components[1]. Gastric carcinosarcoma is rare, and only 56 cases have been reported, mostly in Japan, since the first report by Queckenstadt in 1904[2]. The sarcoma component was considered to be myogenic, rhabdomyoblastic, chondroblastic or osteoblastic in each case reported[3]. Most patients with gastric carcinosarcoma generally have an unfavorable outcome, due to the advanced stage at the time of diagnosis. The mean survival period is 10-15 mo[4].

Gastrointestinal mesenchymal tumors expressing c-kit are classified as gastrointestinal stromal tumors (GISTs)[5], as they are derived from intestinal pacemaker Cajal cells[6,7]. There have been no reports of carcinosarcoma in which the sarcoma component was classified as a malignant GIST, but a few recent cases of synchronous adenocarcinoma and GIST in the stomach were reported[8,9]. Tyrosine kinase inhibitors (imatinib), which can selectively inhibit the enzymatic activity of several tyrosine kinase receptors including c-kit, are now considered adjuvant therapy for GISTs after complete resection in high-risk patients[10]. Recently, radiation therapy has also attracted considerable attention as a treatment option for malignant GISTs[11-14].

Here, we report an advanced case of gastric carcinosarcoma with c-kit expression. Radiation therapy after surgical resection led to an excellent response regarding recurrent tumors as observed by computed tomography (CT).

CASE REPORT
A 70-year-old man was referred to our hospital for dysphagia. He did not drink alcohol, though he had smoked heavily 15 years prior to admission. Laboratory tests showed a low hemoglobin level (12.3 g/dL; normal range: 13.6-16.7 g/dL) and markedly elevated serum alpha-fetoprotein (3019 ng/mL; normal range: < 13.4 ng/mL). Gastroscopy revealed a large exophytic tumor occupying most of the upper anterior wall of the stomach (Figure 1A). CT demonstrated many enlarged lymph nodes (maximum diameter: 25 mm) in the para-aortic and hepatohilar regions (Figure 1B). There was no sign of hematogenic dissemination in any organ.

To increase the chance of a curative operation by tumor downstaging, we applied a neoadjuvant concurrent chemotheraphy consisting of tegafur, gimestat, and ostastat potassium (80 mg/d, oral for three weeks), and cisplatin (60 mg/m² body surface area, drip infusion on day 8). A CT scan showed no reduction of tumor size after one course of the adjuvant chemotherapy. We decided to perform surgical resection of the tumor because the symptoms of appetite loss and malnutrition caused by the primary tumor were potential risks for discontinuation of treatment thereafter. A total gastrectomy with dissection of regional lymph nodes including hepatohilar, common hepatic artery and para-aortic regions was performed.

The resected stomach had a 75 mm × 75 mm exophytic and lobulated, Borrmann type III tumor with a central ulceration occupying most of the upper anterior wall and involving all layers of the gastric wall (Figure 2A). Many regional lymph nodes were enlarged and tumor metastasis was histologically revealed in 4 of 11 nodes. Histology also revealed that the gastric tumor consisted of biphasic components of tubular adenocarcinoma and spindle cell sarcoma (Figure 2B), thus the tumor was classified as a carcinosarcoma. Both epithelial and mesenchymal cell elements existed together in each nest that was replaced by sarcoma cells in stromal areas of the adenocarcinoma (Figure 2C and D). The primary tumor included a transitional mixed part of two pure areas of carcinoma and sarcoma components (Figure 2E). Immunohistochemistry revealed the carcinoma component was positive for cytokeratin (AE1/AE3), alpha-fetoprotein and epithelial membrane antigen while the sarcoma component expressed c-kit (CD117) and CD34, in addition to smooth muscle actin, desmin and vimentin (Table 1, Figure 3). Resected lymph nodes also contained biphasic structures consisting of carcinoma and sarcoma. The carcinomatous component was more prominent than the sarcoma component, and a few sarcoma cells were immunopositive for c-kit. The cancer was postoperatively determined as stage IV according to the TNM classification (pT2, N2, M1, P0).

Nine months after the surgical operation, CT revealed enlarged lymph nodes in the hepatohilar and para-aortic regions (Figure 4A) accompanied by no definitive symptoms; there was no evidence of dissemination. Irradiation with 50 Gy (total dose) was performed to these lymph nodes, resulting in marked decreases in size (Figure 4B). Seventeen months after the operation, a CT scan revealed tumor metastasis to the mediastinal lymph nodes at the trachea bifurcation level (Figure 4C), which were markedly reduced in size after 50 Gy irradiation (Figure 4D).

The patient died 22 mo after gastrectomy as a result of respiratory failure due to bronchopneumonia and multiple lung metastases. An autopsy revealed not only lymphogenic metastasis of retroperitoneal, hepatohilar, mediastinal and supraclavicular lymph nodes, but also hematogenic metastases in the liver, lung, kidney, adrenals, and vertebral bone. The majority of the irradiated tumors were necrotic in the surrounding tissues, and the remaining, viable tumor cells of these metastatic lesions displayed adenocarcinoma morphology.

DISCUSSION
Although the histogenesis of carcinosarcoma still remains...
Figure 1 Tumor presentation. A: Gastroscopy revealed a large exophytic and lobular tumor occupying the upper part of the stomach; B: Computed tomography demonstrated a large tumor in the gastric wall and enlarged lymph nodes around the stomach (arrow).

Figure 2 Histopathology. A: Surgical resection revealed a large tumor (75 mm × 75 mm) with central ulceration (Borrmann type III) occupying the anterior wall of the upper body of the stomach; Hematoxylin and eosin staining revealed B: Biphasic structure consisting of tubular adenocarcinoma and spindle cell sarcoma (20 ×); C: Epithelial components showing that the parenchyma structure of the common gastric adenocarcinoma was surrounded with sarcomatous stroma (200 ×); D: Sarcomatous cells proliferating diffusely in a stream pattern (200 ×); E: Two transitional areas of carcinoma and sarcoma components (20 ×).

| Tested antigens          | Present CS case | Reported GIST cases | Reported CS cases |
|--------------------------|-----------------|---------------------|-------------------|
|                          | Carcinoma       | Sarcoma             | Carcinoma         | Sarcoma         |
| Cytokeratin (AE1/AE3)    | 3+              | -                   | 3+ (90%-100%)     | -               |
| Epithelial membrane antigen | 1+              | -                   | 1+ (70%)          | -               |
| E-cadherin               | 3+              | -                   | -                 | -               |
| Alpha-fetoprotein        | +/-             | -                   | +/- (-)           | -               |
| c-kit (CD117)            | -               | 1+                  | 1+ (20%-30%)      | 2+              |
| CD34                     | -               | 2+                  | 3+ (70%)          | -               |
| Smooth muscle actin      | -               | 2+                  | 1+ (2%-4%)        | -               |
| Desmin                   | -               | 2+                  | -                 | 2+              |
| S100                     | -               | -                   | -                 | -               |
| Vimentin                 | -               | 3+                  | -                 | 3+              |

CS: Carcinosarcoma; GIST: Gastrointestinal stromal tumor. 3+: Positive in all tumor cells; 2+: Positive in most tumor cells; 1+: Positive in some tumor cells; +/-: Positive in a few tumor cells.
gastrointestinal non-epithelial neoplasms that likely originates from mesenchymal cells that control gut motility. GIST is mainly composed of spindle shaped cells and/or polygonal epitheloid cells, though the malignant type likely shows more atypical features in nuclear morphology. These tumor cells are immunopositive for stem cell markers such as c-kit and CD34. Miettinen et al. stated that c-kit expression and signaling are indicators of mutation, and represent diagnostic uncertain, previous reports have suggested two theories. There is a report of an esophageal carcinosarcoma thought to be derived from a multipotent progenitor or stem cell with the ability to pursue both epithelial and mesenchymal differentiation. Another report of esophageal carcinosarcoma suggests that the tumor originates from the collision of two different types of malignancies with separate epithelial and stromal cell line origins. In contrast, GIST is one of the gastrointestinal non-epithelial neoplasms that likely originates from mesenchymal cells that control gut motility. GIST is mainly composed of spindle shaped cells and/or polygonal epitheloid cells, though the malignant type likely shows more atypical features in nuclear morphology. These tumor cells are immunopositive for stem cell markers such as c-kit and CD34. Miettinen et al. stated that c-kit expression and signaling are indicators of mutation, and represent diagnostic
criteria for GISTs. The c-kit expression in the sarcoma component in our case suggests a histogenesis similar to that of GIST. Furthermore, the origin of tumor cells in our case may be a common precursor of various intestinal cells, including smooth muscle and Cajal cells. However, it is unclear why epithelial and mesenchymal cell components were coexisting.

The initial clinical presentation of gastric carcinosarcoma resembles that of gastric carcinoma, with signs such as appetite loss, dysphagia, abdominal pain and anemia due to blood loss from the tumor [11]. Moreover, discriminating between these by conventional radiologic examinations such as CT scan and barium gastrography is difficult due to the lack of specific features. Endoscopic findings generally demonstrate polyloid and lobular configuration with or without ulceration in the center [12]. Gastric carcinosarcoma has a lower incidence of metastasis than gastric carcinoma, but a high mortality rate [13]. In fatal cases, however, metastases are found at various sites. Postsurgical survival of patients with gastric carcinosarcoma is less than ten months after diagnosis [14].

Definitive treatment for gastric carcinosarcoma has not been established, and currently, there are no reports describing effective chemotherapy or radiotherapy. Surgical resection is the only curative modality in cases where the tumor remains in the stomach without distant metastasis [15]. The prognosis is worse in cases of advanced clinical stage, and thus a therapeutic approach other than surgery should be considered. In the case presented here, lymph node metastasis was identified at the time of diagnosis. Surgical resection of the primary tumor and extensive lymph node dissection were performed to minimize tumor burden in the body. Although imatinib is widely accepted for the treatment of GIST, its effect would have been limited in this case as the carcinomatous component did not show c-kit expression. There has been no study reported so far regarding imatinib mesylate for the treatment of gastric carcinosarcoma.

Though not often considered for GISTs, some recent publications provide insight into the efficacy of radiation therapy [16-18]. Cuaron et al. [19] reported local control in 15/17 treated GISTs. In our case, radiation therapies of 50 Gy each decreased the size of metastases in the para-aortic and hepatic hilar regions. Moreover, discriminating between these by conventional radiologic examinations such as CT scan and barium gastrography is difficult due to the lack of specific features. Endoscopic findings generally demonstrate polyloid and lobular configuration with or without ulceration in the center [20]. Gastric carcinosarcoma has a lower incidence of metastasis than gastric carcinoma, but a high mortality rate [21]. In fatal cases, however, metastases are found at various sites. Postsurgical survival of patients with gastric carcinosarcoma is less than ten months after diagnosis [22].

Definitive treatment for gastric carcinosarcoma has not been established, and currently, there are no reports describing effective chemotherapy or radiotherapy. Surgical resection is the only curative modality in cases where the tumor remains in the stomach without distant metastasis [23]. The prognosis is worse in cases of advanced clinical stage, and thus a therapeutic approach other than surgery should be considered. In the case presented here, lymph node metastasis was identified at the time of diagnosis. Surgical resection of the primary tumor and extensive lymph node dissection were performed to minimize tumor burden in the body. Although imatinib is widely accepted for the treatment of GIST, its effect would have been limited in this case as the carcinomatous component did not show c-kit expression. There has been no study reported so far regarding imatinib mesylate for the treatment of gastric carcinosarcoma.

Though not often considered for GISTs, some recent publications provide insight into the efficacy of radiation therapy [24-26]. Cuaron et al. [27] reported local control in 15/17 treated GISTs. In our case, radiation therapies of 50 Gy each decreased the size of metastases in the para-aortic and mediastinal lymph nodes, which appeared as cytoreductive effects upon autopsy, and reduced risks of respiratory trouble and jaundice. However, the relation between c-kit expression and response to radiation is not known, and further studies are needed to examine this.

Although evidence of a survival benefit from combined adjuvant chemotherapy has not been demonstrated, our case indicates a prolonged survival (22 mo) with radiotherapy after tumor resection. Therefore, to improve survival and prognosis of gastric carcinosarcoma, intensive surgery and additional radiation therapy to metastatic foci should be considered, especially in cases of tumors with c-kit expression.

**REFERENCES**

1. **Tanimura H**, Furuta M. Carcinosarcoma of the stomach. *Am J Surg* 1967; 113: 702-709 [PMID: 6021448 DOI: 10.1016/0002-9610(67)90325-X]
2. **Queckenstedt HHG**. *Ueber Karzinosarkome*. Germany: Leipzig, 1904: 1-52
3. **Randjelovic T**, Filipovic B, Babic D, Cemerikic V, Filipovic B. Carcinosarcoma of the stomach: a case report and review of the literature. *World J Gastroenterol* 2007; 13: 5533-5536 [PMID: 17907304]
4. **Teramachi K**, Kanomata N, Hasebe T, Ishii G, Sugito M, Ochiai A. Carcinosarcoma (pure endocrine cell carcinoma with sarcoma components) of the stomach. *Pathol Int* 2003; 53: 552-556 [PMID: 12895235 DOI: 10.1046/j.1440-1827.2003.01508.x]
5. **Hirota S**, Isono K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawanishi K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998; 279: 577-580 [PMID: 9438854 DOI: 10.1126/science.279.5330.577]
6. **Koelz M**, Wick N, Winkler T, Laengle F, Wrba F. The impact of c-kit...
mutations on histomorphological risk assessment of gastrointestinal stromal tumors. *Eur Surg* 2007; 39: 45-53 [DOI: 10.1007/s10353-006-0299-8]

7. **Miettinen M**, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch* 2001; 438: 1-12 [PMID: 11213830 DOI: 10.1007/s004280000338]

8. **Miettinen M**, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. *Eur J Cancer* 2002; 38 Suppl 5: S39-S51 [PMID: 12528772 DOI: 10.1016/S0959-8049(02)80602-5]

9. **Uchiyama S**, Nagano M, Takahashi N, Hidaka H, Matsuda H, Nagaoka K, Maehara N, Horiezzuka M, Chijiiwa K. Synchronous adenocarcinoma and gastrointestinal stromal tumors of the stomach treated laparoscopically. *Int J Clin Oncol* 2007; 12: 478-481 [PMID: 18071869 DOI: 10.11007/s10147-007-06840-8]

10. **Yamamoto D**, Hamada Y, Tsukuba Y, Kawakami K, Yamamoto C, Yamamoto M. Simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) in the stomach: case report. *World J Surg Oncol* 2012; 10: 6 [PMID: 22230934 DOI: 10.1186/1477-7819-10-6]

11. **Demetri GD**, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Kieser B, Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Kieser B, Singer S, Janiak M, Fletcher JA, Silverman SG, Silberman SL, Capdevile R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002; 347: 472-480 [PMID: 12181401 DOI: 10.1056/NEJMoa020461]

12. **Knowlton CA**, Brady LW, Heintzelman RC. Radiotherapy in the treatment of gastrointestinal stromal tumor. *Rare Tumors* 2011; 3: e35 [PMID: 22355490 DOI: 10.4081/rt.2011.e35]

13. **Ulsenheimer K**. Legal liability problems in outpatient operations. View from an anesthesiological perspective. *Anasthesist* 2012; 61: 156-162 [PMID: 22354404 DOI: 10.4081/rt.2011.e49]

14. **Cuaron JJ**, Goodman KA, Lee N, Wu AJ. External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors. *Radiat Oncol* 2013; 8: 274 [PMID: 24267287 DOI: 10.1186/1748-717X-8-274]

15. **Corbin KS**, Kindler HL, Liaw SV. Considering the role of radiation therapy for gastrointestinal stromal tumor. *Onco Targets Ther* 2014; 7: 713-718 [PMID: 24872712]

16. **Ota S**, Kato A, Kobayashi H, Yonezumi M, Yamagushi J, Musashi M, Imamura M, Asaka M. Monoclonal origin of an epithelial gastrointestinal carcinosarcoma producing granulocytosis stimulating factor: a case report. *Cancer* 1998; 82: 2102-2111 [PMID: 9610689 DOI: 10.1002/(SICI)1097-0142(19980601)82::11<2102::AID-CNCR4>3.0.CO;2-X]

17. **Ikeda Y**, Kosugi S, Nishikura K, Ohashi M, Kanda T, Kobayashi T, Hatakeyama K. Gastric carcinosarcoma presenting as a huge epigastric mass. *Gastric Cancer* 2007; 10: 63-68 [PMID: 17334721 DOI: 10.1007/s10120-006-0404-4]

18. **Choi KW**, Lee WY, Hong SW, Chang YG, Lee B, Lee HK. Carcinosarcoma of the stomach: a case report. *J Gastrointestinal Oncol* 2013; 13: 69-72 [PMID: 23610722 DOI: 10.5230/jjgo.2013.13.1.69]

19. **Ransal M**, Kaneko M, Gordon RE. Carcinosarcoma and separate carcinoid tumor of the stomach. A case report with light and electron microscopic studies. *Cancer* 1982; 50: 1876-1881 [PMID: 7116311 DOI: 10.1002/1097-0142(19821101)50::11<1876::AID-CNCR2820500937>3.0.CO;2-T]

20. **Sato Y**, Shimozono T, Kawano S, Toyoda K, Onose K, Asada Y, Hayashi T. Gastric carcinosarcoma, coexistence of adenosquamous carcinoma and rhabdomyosarcoma: a case report. *Histopathology* 2001; 39: 543-544 [PMID: 11737318 DOI: 10.1046/j.1365-2559.2001.1301e.x]

21. **Kisiluk J**, Gryko M, Guzinska-Ustymowicz K, Kemonia A, Kedra B. Immunohistochemical diagnosis of gastrointestinal stromal tumors - an analysis of 80 cases from 2004 to 2010. *Adv Clin Exp Med* 2013; 22: 33-39 [PMID: 23468260]

**Gohongi T et al.** Gastric carcinosarcoma with c-kit expression
